Perrigo InvestorRoom http://perrigo.investorroom.com/ Perrigo Provides Update On 2016 Form 10-K Filing http://perrigo.investorroom.com/2017-03-16-Perrigo-Provides-Update-On-2016-Form-10-K-Filing - Continues to work with independent auditor, and expects to file its Form 10-K as soon as practical Thu, 16 Mar 2017 16:01:00 -0400 http://perrigo.investorroom.com/2017-03-16-Perrigo-Provides-Update-On-2016-Form-10-K-Filing Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine® Foam http://perrigo.investorroom.com/2017-03-08-Perrigo-Announces-First-To-Market-Launch-Of-The-OTC-Store-Brand-Equivalent-To-Womens-Rogaine-R-Foam Wed, 08 Mar 2017 08:35:00 -0500 http://perrigo.investorroom.com/2017-03-08-Perrigo-Announces-First-To-Market-Launch-Of-The-OTC-Store-Brand-Equivalent-To-Womens-Rogaine-R-Foam Perrigo Provides 2016 Form 10-K Update http://perrigo.investorroom.com/2017-03-07-Perrigo-Provides-2016-Form-10-K-Update Tue, 07 Mar 2017 16:03:00 -0500 http://perrigo.investorroom.com/2017-03-07-Perrigo-Provides-2016-Form-10-K-Update Perrigo Announces FDA Final Approval For The Generic Version Of Axiron® Topical Solution, 30 mg/1.5 mL http://perrigo.investorroom.com/2017-03-01-Perrigo-Announces-FDA-Final-Approval-For-The-Generic-Version-Of-Axiron-R-Topical-Solution-30-mg-1-5-mL Wed, 01 Mar 2017 08:55:00 -0500 http://perrigo.investorroom.com/2017-03-01-Perrigo-Announces-FDA-Final-Approval-For-The-Generic-Version-Of-Axiron-R-Topical-Solution-30-mg-1-5-mL Perrigo Company plc Reports Select Preliminary Unaudited Calendar Year 2016 Financial Results And Initial Calendar Year 2017 Guidance http://perrigo.investorroom.com/2017-02-27-Perrigo-Company-plc-Reports-Select-Preliminary-Unaudited-Calendar-Year-2016-Financial-Results-And-Initial-Calendar-Year-2017-Guidance Mon, 27 Feb 2017 16:05:00 -0500 http://perrigo.investorroom.com/2017-02-27-Perrigo-Company-plc-Reports-Select-Preliminary-Unaudited-Calendar-Year-2016-Financial-Results-And-Initial-Calendar-Year-2017-Guidance